Morria Biopharmaceuticals
London
About Morria Biopharmaceuticals
Morria Biopharmaceuticals, a biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs. The company’s products in Phase 2a clinical pipeline include MRX-4, a nasal spray for treating allergic rhinitis or hay fever, as well as MRX-6, a topical cream for treating contact dermatitis, a common type of eczema. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis and dry eye; MRX-5 used in the treatment of inflammatory bowel disease; and CFX-1 for the treatment of cystic fibrosis. The company is headquartered in London, the United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $14.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2013)
- Ticker: otcqb:MRRBY
- Website: celsustx.com
- Phone: +44 (0)20 3322 1321
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/morria-biopharmaceuticals-1960090 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.